Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL: Research paper

British Journal of Haematology

Volumn 149, Issue 2, 2010, Pages 237-243

  Linch, David C ^a,i   Yung, Lynny ^a   Smith, Paul ^a   MacLennan, Ken ^b   Jack, Andrew ^b   Hancock, Barry ^c   Cunningham, David ^d   Hoskin, Peter ^e   Qian, Wendi ^a   Holte, Harald ^f   Boesen, Anne Marie ^f   Grigg, Andrew ^g   Browett, Peter ^g   Trneny, Marek ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Department of Pathology   (Canada)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

^f Nordic Lymphoma Group   (United States)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autologous transplantation; High grade NHL; Non Hodgkin Lymphoma; Poor prognosis

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; PREDNISOLONE; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 77949830857     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08081.x     Document Type: Article

References (24)

1. Betticher, D.C., Martinelli, G., Radford, J., Kaufmann, M., Dyer, M., Kaiser, U., Aulitzky, W.E., Beck, J., von Rohr, A., Kovascovics, T., Cogliatta, S., Cina, S., Maibach, R., Cerny, T. Linch, D.C. (2006) Sequential high dose chemotherapy as initial treatment for aggressive subtypes of non-Hodkin Lymphoma: results of the international randomised Phase III trial (Mistral). Annals of Oncology, 10, 1546 1552.
2. Coiffier, B., Lepage, E., Briere, J., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
3. Feugier, P., van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. Coiffier, B. (2005) Long-term results fo the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117 4126.
4. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A. Jr. Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002 1006.
5. Gianni, A.M., Bregni, M., Siena, S., Brambilla, C., Di Nicola, M., Lombardi, F., Gandola, L., Tarella, C., Pileri, A., Ravagnani, F., Valagussa, P. Bonadonna, G. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New England Journal of Medicine, 336, 1290 1297.
6. Gisselbrecht, C., Lepage, E., Molina, T., Quesnel, B., Fillet, G., Lederlin, P., Coiffier, B., Tilly, H., Gabarre, J., Guilmin, F., Hermine, O. Reyes, F. Groupe d'Etude des Lymphomes de l'Adulte (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. Journal of Clinical Oncology, 20, 2472 2479.
7. Greb, A., Bohlius, J., Schiefer, D., Schwarzer, G., Schulkz, H. Engert, A. (2008) High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin's Lymphoma in adults. Cochrane Database of Systematic Reviews Issue 1. Art.No.CD004024, doi :.
8. Gribben, J.G., Goldstone, A.H., Linch, D.C., Taghipour, G., McMillan, A.K., Souhami, R.L., Earl, H. Richards, J.D.M. (1989) Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional dose chemotherapy. Journal of Clinical Oncology, 7, 1621 1629.
9. Haioun, C., Lepage, E., Gisselbrecht, C., Coiffier, B., Bosly, A., Tilly, H., Morel, P., Nouvel, C., Herbrecht, R. D'Agay, M.F. (1994) Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Journal of Clinical Oncology, 12, 2543 2551.
10. Haioun, C., Lepage, E., Gisselbrecht, C., Bastion, Y., Coiffier, B., Brice, P., Bosly, A., Dupriez, B., Nouvel, C., Tilly, H., Lederlin, P., Biron, P., Briere, J., Gaulard, P. Reyes, F. (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective LNH87.2. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 15, 1131 1137.
11. Haioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B., Brice, P., Bosly, A., Morel, P., Nouvel, C., Tilly, H., Lederlin, P., Sebban, C., Brière, J., Gaulard, P. Reyes, F. (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte study. Journal of Clinical Oncology, 18, 3025 3030.
12. Kaiser, U., Uebelacker, I., Abel, U., Birkmann, J., Trumper, L., Schmalenberg, H., Karakas, T., Metzner, B., Hossfeld, D., Bischoff, H., Franke, A., Reiser, M., Muller, P., Mantovani, L., Grundeis, M., Rothmann, F., von Seydewitz, C.-U., Mesters, R., Steinhauer, E., Krahl, D., Schumacher, K., Kneba, M., Baudis, M., Schmitz, N., Pfab, R., Koppler, H., Parwaresch, R., Pfreundschuh, M. Havemann, K. (2002) Randomised study to evaluate the use of high-dose therapy as part of primary treatment for 'aggressive' lymphoma. Journal of Clinical Oncology, 20, 4413 4419.
13. Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., MacMillan, A.K., Chopra, R.J., Milligan, D. Vaughan Hudson, G. (1993) Dose intensification with autologous bone marrow transplantation is effective in relapsed and resistant Hodgkin's Disease: results of a BNLI randomized trial. Lancet, 341, 138 142.
14. Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. Goldstone, A.H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 13, 588 595.
15. Milpied, N., Deconinck, E., Gaillard, F., Delwail, V., Foussard, C., Berthou, C., Gressin, R., Lucas, V., Colombat, P. Harousseau, J.L. Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. New England Journal of Medicine, 350, 1287 1295.
16. Pfreundschuh, M., Trümper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., López-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. Loeffler, M. MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma. The Lancet Oncology, 7, 379 391.
17. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trümper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. Loeffler, M. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas; a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9, 105 116.
18. Philip, T., Armitage, J.P., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J.Y., Colombat, P., Goldstone, A.H., Gorin, N.C., Flesh, M., Laporte, J.P., Maraninchi, D., Pico, J., Bosly, A., Anderson, C., Schots, R., Biron, P., Cabanillas, F. Dicke, K. (1987) High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New England Journal of Medicine, 316, 1493 1498.
19. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y., Harousseau, J.L., Coiffier, B., Biron, P., Mandelli, F. Chauvin, F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540 1545.
20. Santini, G., Salvagno, L., Leoni, P., Chisesi, T., De Souza, C., Sertoli, M.R., Rubagotti, A., Congiu, A.M., Centurioni, R., Olivieri, A., Tedeschi, L., Vespignani, M., Nati, S., Soracco, M., Porcellini, A., Contu, A., Guarnaccia, C., Pescosta, N., Majolino, I., Spriano, M., Vimercati, R., Rossi, E., Zambaldi, G., Mangoni, L. Rizzoli, V. (1998) VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non Hodgkin's lymphoma: results of a prospective randomised trial by the non Hodgkin's Lymphoma Cooperative Study Group. Journal of Clinical Oncology, 16, 2798 2802.
21. Shipp, M.A., Harrington, D.P., Anderson, J.R., Armitage, J.O., Bonadonna, G., Brittinger, G., Cabanillas, F., Canellos, G.P., Coiffier, B., Connors, J.M., Cowan, R.A., Crowther, D., Dahlberg, S., Engelhard, M., Fisher, R.I., Gisselbrecht, C., Horning, S.J., Lepage, E., Lister, A., Meerwaldt, J.H., Montserrat, E., Nissen, N.I., Oken, M.M., Peterson, B.A., Tondini, C., Velasquez, W.S. Yeap, B.Y. (1993) A predictive model for aggressive NHL: the International non-Hodgkin's Lymphoma Prognostic factors project. New England Journal of Medicine, 329, 987 994.
22. Simnett, S.J., Stewart, L.A., Sweetenham, J., Morgan, G. Johnson, P.W. (2000) Autologous stem cell transplantation for malignancy: a systematic review of the literature. Clinical and Laboratory Haematology, 22, 61 72.
23. Strehl, J., Mey, U., Glasmacher, A., Djulbegovic, B., Mayr, C., Gorschluter, M., Ziske, C. Schmidt-Wolf, I.G.H. (2003) High dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica, 88, 1304 1315.
24. The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical useage. Cancer, 49, 2112 2135.